HAE
FDA Approves Takhzyro for HAE Prophylaxis in Children
The FDA approved the use of Takhzyro to prevent attacks of hereditary angioedema in children aged 2 to 12 years.
FEBRUARY 6, 2023
FDA Approves Takhzyro for Rare Hereditary Angioedema
Takhzyro is the first monoclonal antibody approved in the United States to prevent attacks of hereditary angioedema ...
AUGUST 27, 2018
Haegarda Reduces Attack Frequency in HAE Patients
Approximately 30% of patients with hereditary angioedema experience weekly attacks, and many are debilitating.
NOVEMBER 7, 2017
Load more